menu
    • menu
    [{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"IGM-8444","moa":"DR5","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"IGM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"IGM-2323","moa":"CD20 x CD3","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"IGM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Medivir","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Birinapant","moa":"SMAC","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.34999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"IGM Biosciences \/ IGM Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ IGM Biosciences"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Medivir","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Birinapant","moa":"SMAC","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"IGM Biosciences \/ IGM Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ IGM Biosciences"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Anti-CSP IgM Antibodies","moa":"CSP","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"IGM Biosciences \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"IGM Biosciences \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"IGM-2323","moa":"CD20 x CD3","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IGM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"IGM-2323","moa":"CD20 x CD3","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IGM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Engineered IgM Antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"IGM Biosciences","amount2":6.1500000000000004,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":6.1699999999999999,"dosageForm":"","sponsorNew":"IGM Biosciences \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"IGM Biosciences \/ Sanofi"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Imvotamab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IGM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"IGM Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"IGM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"IGM-7354","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"IGM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Engineered IgM Antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"IGM Biosciences","amount2":6.1699999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":6.1699999999999999,"dosageForm":"","sponsorNew":"IGM Biosciences \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"IGM Biosciences \/ Sanofi"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Imvotamab","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IGM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"IGM Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"IGM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Bevacizumab","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"IGM Biosciences \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ BofA Securities"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"IGM Biosciences","amount2":6.1699999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":6.1699999999999999,"dosageForm":"","sponsorNew":"IGM Biosciences \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"IGM Biosciences \/ Sanofi"}]

    Find Clinical Drug Pipeline Developments & Deals by IGM Biosciences

    Menu

    IGM Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            IGM Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            IGM Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Sanofi

                            Deal Size : $6,165.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            IGM Biosciences Announces Refocusing of Sanofi Collaboration

                            Details : Under the collaboration, Sanofi will create and develop IgM agonist antibodies will now focus exclusively on immunology/inflammation targets by leveraging proprietary IgM antibody technology platform.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $150.0 million

                            April 17, 2024

                            Lead Product(s) : Antibody

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Sanofi

                            Deal Size : $6,165.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            IGM Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            IGM Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IGM-8444,Bevacizumab,Fluorouracil

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : BofA Securities

                            Deal Size : $80.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            IGM Announces Pricing of $107.3 Million Upsized Public Offering and Concurrent Private Placement

                            Details : The company intends to use the net proceeds for its pipeline development including, IGM-8444, an IgM antibody targeting Death Receptor 5 (DR5) that is being developed for the treatment of patients with solid and hematologic malignancies.

                            Brand Name : IGM-8444

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 22, 2023

                            Lead Product(s) : IGM-8444,Bevacizumab,Fluorouracil

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : BofA Securities

                            Deal Size : $80.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            IGM Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            IGM Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IGM-8444,Bevacizumab,Fluorouracil

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development

                            Details : IGM-8444 is an IgM antibody targeting death receptor 5 (DR5) that is being developed for the treatment of patients with solid tumor including metastatic colorectal cancerand hematologic malignancies.

                            Brand Name : IGM-8444

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 02, 2023

                            Lead Product(s) : IGM-8444,Bevacizumab,Fluorouracil

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            IGM Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            IGM Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Imvotamab

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthrit...

                            Details : IGM-2323 (imvotamab), a novel IgM-based CD20 x CD3 bispecific antibody T cell engager (TCE), cleared two IND applications, enabling the initiation of Phase 1b studies in both severe systemic lupus erythematosus (SLE) and severe rheumatoid arthritis (RA).

                            Brand Name : IGM-2323

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 31, 2023

                            Lead Product(s) : Imvotamab

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            IGM Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            IGM Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IGM-7354

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-7354 in Solid Tumors

                            Details : IGM-7354 is a targeted IL-15/IL-15R IgM immune stimulating antibody for the treatment of patients with solid tumors and hematologic malignancies. IGM-7354 may enhance the immune system’s activity in the tumor microenvironment.

                            Brand Name : IGM-7354

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 17, 2023

                            Lead Product(s) : IGM-7354

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            IGM Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            IGM Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IGM-8444,Bevacizumab,Fluorouracil

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development

                            Details : IGM-8444 is an IgM antibody targeting Death Receptor 5 (DR5) that is being developed for the treatment of patients with solid and hematologic malignancies.

                            Brand Name : IGM-8444

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 09, 2023

                            Lead Product(s) : IGM-8444,Bevacizumab,Fluorouracil

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            IGM Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            IGM Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Imvotamab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IGM Biosciences Presents Data from T cell Engager Portfolio for Hematologic Malignancies at 2022 American Soci...

                            Details : Imvotamab (IGM-2323), the first-in-class CD20xCD3 bispecific IgM antibody with dual mechanisms of action, in patients with advanced B cell malignancies.

                            Brand Name : IGM-2323

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 11, 2022

                            Lead Product(s) : Imvotamab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            IGM Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            IGM Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Engineered IgM Antibody

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Sanofi

                            Deal Size : $6,150.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            IGM Biosciences Announces Closing of Global Collaboration Agreement with Sanofi

                            Details : The collaboration is for the creation, development, manufacture, and commercialization of IgM antibody agonists against three oncology targets and three immunology/inflammation targets.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $150.0 million

                            May 06, 2022

                            Lead Product(s) : Engineered IgM Antibody

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Sanofi

                            Deal Size : $6,150.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            IGM Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            IGM Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Engineered IgM Antibody

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Sanofi

                            Deal Size : $6,165.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets

                            Details : Under collaboration Sanofi and IGM will lead research, develop and commercialize IgM antibody agonists against three oncology targets and three immunology/inflammation targets by leveraging proprietary IgM antibody technology platform.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $150.0 million

                            March 29, 2022

                            Lead Product(s) : Engineered IgM Antibody

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Sanofi

                            Deal Size : $6,165.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            IGM Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            IGM Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IGM-2323

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IGM Biosciences Presents Clinical Data from IGM-2323 in Patients with Advanced B Cell Malignancies at 2021 Ame...

                            Details : Based on the results, two Phase 2 studies are being initiated to assess the safety and efficacy of two doses of IGM-2323, in patients with DLBCL and FL. Data demonstrate that IGM-2323 is highly active against multiple subtypes of relapsed/ refractory non...

                            Brand Name : IGM-2323

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 11, 2021

                            Lead Product(s) : IGM-2323

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth